EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and tolerability of a novel cosmetic growth factor serum when used as part of biweekly diamond tip hydradermabrasion treatments on facial skin

Priscilla Huang iD, Rahul Mehta, Tanja Emmerich, Lily I Jiang, Elizabeth Makino

Journal of Cosmetic Dermatology · 2024

DOI: 10.1111/jocd.16229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Priscilla Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Allergan Aesthetics, an AbbVie Company, Irvine, California, USA. Hauptthemen laut MEDLINE: Cosmetics, Skin Aging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allergan Aesthetics, an AbbVie Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Growth factor preparations have demonstrated effectiveness in reversing age‐related changes in facial skin. TNS® Advanced+ Serum (TNS A+ Serum; SkinMedica®, Allergan Aesthetics, an AbbVie Company) and TNS Advanced+ Pro‐Infusion Serum for DiamondGlow® (DG‐TNS A+; Allergan Aesthetics) combine growth factor technology with active botanical ingredients to target signs of skin aging.

Aims

This prospective clinical study evaluated the effectiveness and tolerability of biweekly facial hydradermabrasion (DiamondGlow [DG]; Allergan Aesthetics) plus DG‐TNS A+ combined with at‐home topical TNS A+ Serum.

Methods

Females aged 25–65 years with mild to severe facial photodamage received 6 biweekly DG plus DG‐TNS A+ in‐office treatments with at‐home twice‐daily TNS A+ Serum for 12 weeks. Investigator‐assessed clinical grading of multiple skin attributes, subject self‐assessments, instrumentation measurements, and clinical grading of irritation parameters (0–3, none to severe) were conducted at Visit 1, Day 3, and biweekly from Weeks 2–12.

Results

Twenty‐nine women (Fitzpatrick skin types II–VI; 52% White, 41% African American) were enrolled. Immediate significant improvements after 1 DG plus DG‐TNS A+ treatment were observed for fine lines/wrinkles, skin smoothness (visual and tactile), radiance, and hydration (all p ≤ 0.004). From Weeks 6–12, all investigator‐assessed parameters showed significant improvements versus baseline (all p ≤ 0.002 at Week 12). Mean tolerability scores were

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CosmeticsSkin AgingFemaleHumansAdministration, CutaneousProspective StudiesTreatment OutcomeSkinIntercellular Signaling Peptides and Proteins

Stichwörter der Autor:innen

conditionedculture mediafibroblastfibroblast growth factorsrejuvenation

Substanzen

CosmeticsIntercellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Allergan Aesthetics, an AbbVie Company, Irvine, California, USA.
  • SGS Stephens Inc., Richardson, Texas, USA.

ORCID-Profile: Priscilla Huang

Förderung

  • Allergan Aesthetics, an AbbVie Company

Zitieren

APA

Huang, P., Mehta, R., Emmerich, T., Jiang, L. I., & Makino, E. (2024). Efficacy and tolerability of a novel cosmetic growth factor serum when used as part of biweekly diamond tip hydradermabrasion treatments on facial skin. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16229

Vancouver

Huang P, Mehta R, Emmerich T, Jiang LI, Makino E. Efficacy and tolerability of a novel cosmetic growth factor serum when used as part of biweekly diamond tip hydradermabrasion treatments on facial skin. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16229

BibTeX
@article{Huang2024,
  author = {Huang, Priscilla and Mehta, Rahul and Emmerich, Tanja and Jiang, Lily I and Makino, Elizabeth},
  title = {Efficacy and tolerability of a novel cosmetic growth factor serum when used as part of biweekly diamond tip hydradermabrasion treatments on facial skin},
  journal = {Journal of Cosmetic Dermatology},
  year = {2024},
  doi = {10.1111/jocd.16229}
}
Kostenlos starten →